P0896 - A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study
Silvio Danese, MD, PhD1, Bruce E.. Sands, MD, FACG2, Brian G.. Feagan, MD3, Vipul Jairath, MBChB3, Remo Panaccione, MD4, Laurent Peyrin-Biroulet, MD, PhD5, Peter M.. Irving, MA, MD6, Stefan Schreiber, MD7, Iris Dotan, MD8, Marc Ferrante, MD, PhD9, Geert R. D'Haens, MD, PhD10, Stephen Jones, MBBS, BSc11, Marcelo Freire, PhD12, Dirk Lindner, MSc13, Shashi Adsul, MD, MBA12, Pooja Oberai, MD12, Jean-Frédéric Colombel, MD2 1Humanitas Clinical and Research Center - IRCCS, Rozzano and Humanitas University, Pieve Emanuele, Milan, Lombardia, Italy; 2Icahn School of Medicine at Mount Sinai, New York, NY; 3Western University, London, ON, Canada; 4University of Calgary, Calgary, AB, Canada; 5INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France; McGill University Health Centre, Montreal, QC, Canada, Nancy, Lorraine, France; 6Guy’s and St. Thomas’ NHS Foundation Trust, London, England, United Kingdom; 7University Hospital, Kiel, Schleswig-Holstein, Germany; 8Rabin Medical Center, Tel Aviv University, Tel Aviv, Tel Aviv, Israel; 9University Hospitals, Leuven, Vlaams-Brabant, Belgium; 10Amsterdam University Medical Center, Amsterdam, Limburg, Netherlands; 11Takeda, UK, England, United Kingdom; 12Takeda, Cambridge, MA; 13Takeda, Zurich, Zurich, Switzerland
Introduction: Remission rates in patients with Crohn’s disease (CD) suggest a therapeutic ceiling when treated with a single advanced targeted treatment (ATT) or ATT plus immunomodulator, representing an unmet need for alternative strategies. Dual targeted therapy (DTT)/advanced combination therapy has potential to provide an additive or synergistic benefit by targeting >1 pathway. Vedolizumab (VDZ) and upadacitinib (UPA) are treatments for moderate to severe CD with different mechanisms of action, and in silico models suggest their combination could modulate a high number of pathways relevant to the pathophysiology of CD. The VICTRIVA trial aims to compare the efficacy and safety of induction with VDZ + UPA vs VDZ alone.
Methods: The primary objective of VICTRIVA (NCT06227910), a randomized, double-blind, controlled, phase 3b trial in biologic experienced and biologic naïve adult patients with CD, is to assess whether induction with VDZ + UPA improves rates of clinical remission and endoscopic response at week(W) 12 vs VDZ alone. Patients will be randomized 1:1 to 12 week induction with VDZ + UPA (Group 1) or VDZ + placebo (Group 2) (Figure). W12 responders will enter the maintenance arm from W13-52 (VDZ monotherapy every 8 weeks [Q8W] to W52; possible Q4W escalation if needed). W12 nonresponders will enter prolonged induction Substudy 1 (VDZ + UPA to W24, followed by VDZ monotherapy). Patients who lose response during maintenance will be escalated to Q4W, or enter rescue treatment Substudy 2 (DTT for 12 weeks, then VDZ Q4W). Assessments include Crohn’s Disease Activity Index (CDAI) and patient reported outcomes at W2,6,12 during induction and in the maintenance and substudies through W52, Simple Endoscopic Score for Crohn’s Disease (SES-CD) at screening, W12 and 52, and safety at each visit.
Results: 396 patients (198 in Groups 1 and 2) will be enrolled globally. Co-primary endpoints will be CDAI clinical remission (score < 150) and SES-CD endoscopic response ( >50% score reduction) at W12. Key secondary endpoints include PRO2 clinical remission at W12, and CDAI clinical remission, SES-CD endoscopic response and PRO2 clinical remission at W52. Safety endpoints will include adverse events and adverse events of special interest.
Discussion: The VICTRIVA trial is designed to evaluate the efficacy and safety of VDZ in combination with UPA relative to VDZ monotherapy in an attempt to break the current therapeutic ceiling for inducing remission in CD and improve long-term outcomes.
Figure: aVDZ IV 300 mg at Weeks 0, 2, 6, and 10. bUPA oral 45 mg once daily. cVDZ IV 300 mg Q8W, possible escalation to Q4W. dVDZ IV 300 mg Q4W. eUPA oral 30 mg once daily for patients initially assigned to Group 1, 45 mg once daily for patients initially assigned to Group 2. CDAI, Crohn’s Disease Activity Index; PRO2, Patient Reported Outcome; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UPA, upadacitinib; VDZ, vedolizumab.
Laurent Peyrin-Biroulet: AbbVie – Grant/Research Support, Personal fees. Allergan – Personal Fees. Alma Bio Therapeutics – Personal Fees. Amgen – Personal Fees. Applied Molecular Transport – Personal Fees. Arena – Personal Fees. Biogen – Personal Fees. Boehringer Ingelheim – Personal Fees. Bristol Myers Squibb – Personal Fees. Celgene – Personal Fees. Celltrion – Personal Fees. CTMA – Stock Options. Enterome – Personal Fees. Enthera – Personal Fees. Ferring – Personal Fees. Fresenius Kabi – Personal Fees. Genentech – Personal Fees. Gilead – Personal Fees. Hikma – Personal Fees. InDex Pharmaceuticals – Personal Fees. Janssen – Personal Fees. Lilly – Personal Fees. MSD – Grant/Research Support, Personal Fees. Mylan – Personal Fees. Nestlé – Personal Fees. Norgine – Personal Fees. Oppilan Pharma – Personal Fees. OSE Immunotherapeutics – Personal Fees. Pfizer Inc – Personal Fees. Pharmacosmos – Fees. Samsung Bioepis – Personal Fees. Sandoz – Personal Fees. Sterna – Personal Fees. Sublimity Therapeutics – Personal Fees. Takeda – Grant/Research Support, Personal Fees. Tillotts – Personal Fees. Vifor – Personal Fees.
Silvio Danese, MD, PhD1, Bruce E.. Sands, MD, FACG2, Brian G.. Feagan, MD3, Vipul Jairath, MBChB3, Remo Panaccione, MD4, Laurent Peyrin-Biroulet, MD, PhD5, Peter M.. Irving, MA, MD6, Stefan Schreiber, MD7, Iris Dotan, MD8, Marc Ferrante, MD, PhD9, Geert R. D'Haens, MD, PhD10, Stephen Jones, MBBS, BSc11, Marcelo Freire, PhD12, Dirk Lindner, MSc13, Shashi Adsul, MD, MBA12, Pooja Oberai, MD12, Jean-Frédéric Colombel, MD2. P0896 - A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.